FR940603-2-00062 FR940603-2-00043 [Docket No. 94N&hyph;0194] Apothecon, et al.; Withdrawal of Approval of Six Abbreviated Antibiotic Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of six abbreviated antibiotic applications (AADA's). The holders of the AADA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. EFFECTIVE DATE: July 5, 1994. FOR FURTHER INFORMATION CONTACT: Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. SUPPLEMENTARY INFORMATION: The holders of the AADA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing. ␣ 1AADA No. 1Drug 1Applicant 61&hyph;911 Kanamycin Sulfate Capsules, U.S.P. 500 miligrams (mg) Apothecon, P.O. Box 4500, Princeton, NJ 08543&hyph;4500. 61&hyph;981 Neomycin and Polymyxin B Sulfates and Bacitracin Ointment, U.S.P Clay-Park Labs, Inc., 1700 Bathgate Ave., Bronx, NY 10457. 62&hyph;271 Cloxacillin Sodium Capsules, USP, 250 mg Apothecon. 62&hyph;688 Sterile Cefazolin Sodium, U.S.P Fujisawa USA, Inc., Three Parkway North, 3d floor, Deerfield, IL 60015&hyph;2548. 62&hyph;957 Erythromycin Topical Solution, USP, 2% Barre-National, Inc., 333 Cassell Dr., suite 3500, Baltimore, MD 21224. 63&hyph;010 Nystatin and Triamcinolone Acetonide Cream, USP ␣␣Do. Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the AADA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective July 5, 1994. Dated: May 24, 1994. Murray M. Lumpkin, Acting Director, Center for Drug Evaluation and Research. [FR Doc. 94&hyph;13593 Filed 6&hyph;2&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;P
